NxStage wins another nod in the European Union

February 25, 2013 by Sony Salzman

European Union regulators grant CE Mark approval to NxStage Medical's high-flow System 1 home hemodialysis technology, hard on the heels of its approval for nocturnal home dialysis across the pond.

NxStage Medical wins CE Mark for nocturnal dialysis

NxStage Medical (NSDQ:NXTM) won CE Mark approval in Europe for its System 1 technology, which includes new high-flow capabilities to the portable hemodialysis system.

The Lawrence, Mass.-based company is gearing up to distribute this product in the European Union later this year. This win comes on the heels of another CE Mark approval for the nocturnal use of the same System 1 device.

Sign up to get our free newsletters delivered right to your inbox.

"By providing expanded therapy options, high flow enables NxStage therapy to be even better tailored to the clinical and lifestyle needs of a broader range of patients," said CEO Jeffrey Burbank in a statement.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp